Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Measurement of Bioavailability: Pharmacodynamic Methods

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.

Progress in neuro-psychopharmacology & biological psychiatry·2021

Same author

Possible Modulatory Role of ARC Gene Variants in Mood Disorders.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2021

Same author

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology·2021

Same author

Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression.

Current medicinal chemistry·2021

Same author

Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression.

Journal of affective disorders·2020

Same author

Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2020

Search research articles

Related Experiment Video

Updated: Mar 23, 2026

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

Possible biomarkers modulating haloperidol efficacy and/or tolerability.

Stefano Porcelli¹, Concetta Crisafulli², Marco Calabrò²

¹Department of Biomedical & NeuroMotor Sciences, University of Bologna, Italy.

Pharmacogenomics

|March 30, 2016

Summary

Researchers explored potential peripheral biomarkers to monitor Haloperidol (HP) effectiveness in psychosis treatment. While no validated biomarker exists, findings on cytokines, HP metabolites, and genetic markers show promise for future research.

Keywords:

cytokines genetics haloperidol metabolites peripheral biomarkers

More Related Videos

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Related Experiment Videos

Last Updated: Mar 23, 2026

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Area of Science:

Pharmacology
Neuroscience
Biomarker Discovery

Background:

Haloperidol (HP) is a key antipsychotic for psychosis, but its efficacy and adverse drug reactions vary significantly among patients.
This variability suggests individual factors influence HP's mechanism of action and treatment outcomes.
Identifying reliable biomarkers is crucial for personalized treatment and risk assessment.

Purpose of the Study:

To review potential peripheral biomarkers for monitoring and predicting Haloperidol (HP) effectiveness in psychosis treatment.
To identify promising candidates for future biomarker research in clinical settings.

Main Methods:

Systematic review of existing literature on peripheral indicators related to Haloperidol (HP) action.
Analysis of potential biomarkers including cytokines, drug metabolites, and genetic variations.
Evaluation of their relevance to HP efficacy and adverse event prediction.

Main Results:

No single validated peripheral biomarker for Haloperidol (HP) effectiveness is currently established.
Several candidate biomarkers show potential, including specific cytokines, Haloperidol (HP) metabolites, and patient genotypes.
These factors individually and collectively may influence treatment response and side effects.

Conclusions:

Peripheral biomarkers hold promise for personalizing Haloperidol (HP) therapy in psychosis.
Further research into cytokines, HP metabolites, and genotypic biomarkers is warranted to develop predictive tools.
Validated biomarkers could optimize treatment efficacy and minimize adverse drug reactions.